• PDF / 169,808 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 34 Downloads / 147 Views

DOWNLOAD

REPORT

---

1 S

Febrile neutropenia: case report A 43-year-old woman developed febrile neutropenia during treatment with docetaxel and epirubicin for triple negative breast cancer. The woman, who had a history of triple negative breast cancer and had undergone a left modified radical mastectomy started receiving adjuvant chemotherapy with IV epirubicin and IV docetaxel 75 mg/m2 every 3 weeks for six sessions [not all dosages stated]. She developed febrile neutropenia after the first chemotherapy treatment. Therefore, the woman was initiated on granulocyte colony-stimulating factor [drug not specified] from the second chemotherapy session [outcome not stated]. After 2 years, while still in remission, she underwent simple mastectomy on the right side followed by bilateral reconstruction. In the following year, she experienced seizures following headaches, which stabilised later. CT scan and MRI revealed singular CNS metastasis in the left frontal lobe. CT scan of the chest, pelvis and abdomen revealed right hilar metastasis. The CNS metastasis was resected completely which exhibited hormone receptor negative and Her2 positive cancer. Thereafter, she started receiving chemotherapy with trastuzumab and capecitabine, which showed partial response. Later, she developed liver metastasis and recurrence of a right hilar mass. Her performance status was noted to be poor, therefore, she was moved to hospice services. She died after 3 weeks [immediate cause of death not stated]. Katakkar SB. A triple negative breast cancer: What it is not!. Breast Cancer: Targets and Therapy 4: 21-23, 23 Feb 2012. Available from: URL: http://doi.org/10.2147/ 803502263 bctt.s28449

0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 19 Sep 2020 No. 1822